Evidence map›Paper›PMID 18215108›Full record

ReviewPLoS medicine2008

Incorporating molecular tools into early-stage clinical trials.

Robert J Weil

Registry-linked trialAbstract readReviewComment
PubMed Full text at PMC Publisher
In one paragraph

Review in PLoS medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01466868 (A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01466868 phase2terminatednot on this mapstarted 2011, after this paper: background citation

A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

TypeinterventionalSponsorCentre Leon BerardRan2011 to 2014Enrolled22ConditionsDiffuse Large B Cell LymphomaArmsMK2206
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Robert J WeilBrain Tumor and Neuro-Oncology Center, Department of Neurosurgery and the Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States of America. weilr@ccf.org

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Delivery SystemsAnimalsAntineoplastic AgentsBrain NeoplasmsClinical Trials as TopicCombined Modality TherapyDrug Evaluation, PreclinicalErbB ReceptorsGlioblastomaHumansNeoplasm ProteinsNeoplasm Recurrence, LocalProtein Kinase InhibitorsProtein KinasesProtein-Tyrosine KinasesProto-Oncogene Proteins c-aktAntineoplastic AgentsEGFR protein, humanErbB ReceptorsMTOR protein, humanNeoplasm ProteinsProtein Kinase InhibitorsProtein KinasesProtein-Tyrosine KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID18215108
PMCPMC2211557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.